在动物保健方面，默沙东将展示覆盖宠物、家禽、猪、反刍动物和水产五大业务的产品与解决方案。此 外，默沙东将举办多场主题活动，聚焦肿瘤、罕见病及公共卫生等重点领域。(经济日报记者袁勇) 在本届进博会上，默沙东集中展示在中国境内已获批的约30种药物和疫苗，覆盖肿瘤、抗感染、糖尿 病、罕见病等领域，其中包括多款创新药品和新适应证的"进博首秀"。得益于进博会强大的溢出效应， 默沙东去年展示的多款在研药物已陆续在中国境内获批上市。 此外，默沙东今年将展示抗病毒、心血管等多元治疗领域的全球及中国在研管线。目前，默沙东正在中 国推进多个治疗领域的临床研究，预计未来五年将向中国引入40多项新产品和新适应证。 11月5日，第八届进博会开幕。默沙东连续第七年亮相进博会，围绕"创新科学，健康未来"主题，全景 式呈现在前沿科学领域的医疗创新成果，与本土医药企业的研发合作布局，以及进入中国三十多年来对 企业责任的不懈实践。 过去三年，默沙东与包括科伦博泰、恒瑞医药（600276）在内的五家本土医药企业围绕心脑血管、代谢 和肿瘤领域开展了多项研发合作。默沙东研发中国创新合作中心(MCICC)于2024年11月1日正式成立， 致力于深化与中 ...

Group 1: Asset Allocation Strategy - The article emphasizes the importance of adapting asset allocation strategies in response to the evolving global order and industrial transformations, projecting significant changes by 2026 [2][17]. - It suggests a bullish outlook on Chinese A/H stocks due to accelerated economic transformation and enhanced market resilience against risks [3][8]. - The report anticipates a moderate recovery in the Eurozone economy and a stable outlook for Japanese markets, while recommending a cautious approach to Indian equities due to uncertainties [3][4]. Group 2: Equity Market Insights - The article highlights the potential for a "transformation bull market" in China, driven by capital market reforms and economic restructuring, with expectations for the Shanghai Composite Index to surpass 4000 points [8][9]. - It identifies three main drivers for this transformation: the decline of risk-free returns, significant capital market reforms, and increased certainty in China's economic transition [9][10]. - The report recommends focusing on sectors such as technology, manufacturing, and cyclical consumption, with specific stock picks in internet, robotics, and electric vehicles [10]. Group 3: Bond Market Outlook - The report predicts a slight upward trend in Chinese government bond yields due to a stable yet slightly easing monetary policy, while U.S. Treasury yields are expected to decline moderately [4]. - It notes that the risk appetite is recovering, which may lead to upward pressure on interest rates in China, while U.S. inflation expectations are gradually decreasing [4]. Group 4: Commodity Market Analysis - The article expresses a bullish long-term view on gold, driven by the diversification of global central bank reserves and the weakening of the U.S. dollar [5]. - It indicates that oil prices are under pressure due to oversupply, while copper prices are supported by structural demand from AI infrastructure and grid upgrades [5]. Group 5: Currency and Exchange Rate Trends - The article anticipates a continued weak dollar scenario, with the Chinese yuan expected to stabilize or appreciate slightly due to steady domestic economic momentum [6]. - It highlights potential short-term fluctuations in the dollar due to geopolitical factors and domestic economic conditions [6]. Group 6: Pharmaceutical Sector Insights - The report indicates a significant increase in the market value of pharmaceutical stocks held by public funds, rising from 300.9 billion to 409 billion yuan, reflecting a 35.9% increase [13]. - It notes that the proportion of pharmaceutical stocks in public fund holdings has increased, with chemical preparations and other biological products being the most significant segments [13][14]. - Key stocks in the pharmaceutical sector include Heng Rui Medicine, Innovent Biologics, and Mindray Medical, with substantial increases in their market values [14].

Company Overview - The company is focused on strategic planning and main business development, with a significant emphasis on pharmaceutical collaboration with Heng Rui Pharmaceutical [2][9]. - The company has eight production bases, six of which are core facilities, and is optimizing its production capacity and layout [2][4]. Financial Performance - The company reported a significant improvement in sales, with the Lanzhou base achieving approximately CNY 0.88 billion in sales for 2024, and reaching CNY 1.4 billion by June 30, 2025, indicating a notable growth trend [2]. - The company experienced a narrowing of losses in Q3 2023, attributed to intensified market competition and insufficient customer demand for older products [2]. Production Capacity and Utilization - The overall production capacity utilization is currently low due to the cyclical downturn in the pesticide industry and the gradual release of new product capacities [2][4]. - The company is investing in new projects primarily at the Lanzhou and Nantong bases, focusing on innovative pesticide intermediates and pharmaceutical products [5][6]. Research and Development - The company has established four major R&D centers and is enhancing its capabilities in pilot testing, with a focus on anti-viral drug production [7][11]. - The company is pursuing a cautious diversification strategy, concentrating on core areas such as synthetic biology and health, while exploring new materials at an early stage [7][10]. Market Outlook - The agricultural chemical market is expected to stabilize as customer inventory adjustments conclude and demand for innovative products increases [5]. - The company anticipates a balanced development between its pharmaceutical and agricultural businesses, aiming for a 20-30% revenue contribution from the pharmaceutical sector in the coming years [10][11]. Strategic Partnerships - The company has established a strategic partnership with Heng Rui Pharmaceutical, covering all stages from preclinical to commercial production, with over 20 projects currently in progress [9][10]. - The company plans to leverage its CDMO capabilities to enhance customer engagement and expand its market presence [9][10].

Core Insights - The 8th China International Import Expo (CIIE) opened in Shanghai on November 5, 2023, with the theme "Open Up to Create New Opportunities, Collaborate to Share a New Future," attracting participation from 155 countries and regions, with over 4,108 foreign enterprises exhibiting, marking a new high in scale [1][3] Industry Developments - Multinational pharmaceutical companies are increasingly establishing R&D centers in China, with Astellas announcing its first innovation R&D center in Beijing on October 27, 2023, complementing its existing centers in Tokyo, San Francisco, Boston, Chicago, and Cambridge [3][4] - Major pharmaceutical companies like AstraZeneca and Boehringer Ingelheim have announced new investment plans in China, with AstraZeneca planning to invest $2.5 billion (approximately 18 billion RMB) and Boehringer Ingelheim over 5 billion RMB [4][5] - The trend of multinational companies acquiring innovative drug assets in China is accelerating, with companies like Takeda and Pfizer making significant investments to secure innovative drug assets, setting new records for business development (BD) transaction volumes in the Chinese innovative drug market [4][5] Market Positioning - China is evolving from a passive consumer market to a global innovation hub for multinational pharmaceutical companies, participating deeply in the entire process from R&D to production and sales [5][6] - By 2024, over 20% of the top 100 life sciences research institutions in the Nature Index will be in China, and the number of clinical trials initiated in China is expected to approach 2,000, reflecting a significant increase in China's innovation capabilities [6][7] Collaborative Trends - The number of multinational pharmaceutical companies establishing R&D centers in China has surged, with at least eight companies announcing new centers in October 2023 alone, including Eli Lilly, Pfizer, Bayer, and AstraZeneca [8][9] - Eli Lilly has invested over 20 billion RMB in China, focusing on a full industry chain layout from R&D to commercialization, and plans to continue expanding its local collaborations [10][11] Investment and Business Development - The total amount of innovative drug licensing agreements from China has surpassed $100 billion, with significant growth in transaction volumes and values, indicating a robust BD trend in the Chinese pharmaceutical market [15][16] - Notable transactions include Pfizer's $12.5 billion upfront payment for a breakthrough drug and Takeda's recent collaboration with Innovent Biologics involving a potential total deal value of up to $11.4 billion [16][17] Future Outlook - The trend of multinational companies seeking innovative resources in China is expected to continue, driven by the need to fill revenue gaps due to patent expirations in the U.S. and Europe [18][19] - The influence of Chinese biotech on the global market is growing, with projections indicating that by 2040, 35% of FDA-approved innovative drugs may originate from China [19]

Core Viewpoint - The A-share market has shown significant recovery since the third quarter, with active trading and continued foreign investment, particularly in industry leaders and state-owned enterprises [3][5][14]. Group 1: Foreign Investment Trends - As of the end of September, major industry leaders such as Kweichow Moutai, China Ping An, and Wuliangye attracted over 80 foreign institutional investors each [6][5]. - The top three foreign-held A-shares by market value are CATL (265.66 billion), Kweichow Moutai (88.14 billion), and Midea Group (71.65 billion) [6][5]. - Foreign investment in "Chinese state-owned enterprises" has increased, with China Shipbuilding attracting 68 foreign investors, a rise of over 40% from the end of the first half [7][5]. Group 2: Sector Preferences - Foreign investors favor industry leaders, state-owned enterprises, and bank stocks, with seven of the top ten foreign-held A-shares being banks [6][5]. - Notable bank stocks include Nanjing Bank (2.36 billion shares held by 32 foreign investors) and Ningbo Bank (1.60 billion shares held by 42 foreign investors) [6][5]. Group 3: Individual Stock Movements - UBS significantly increased its stake in RuiNeng Technology, becoming the third-largest shareholder, while Goldman Sachs, JPMorgan, and Merrill Lynch entered the top ten shareholders [9][10]. - RuiNeng Technology's stock price has surged over 40% since mid-October, despite a 32.73% decline in net profit year-on-year [12][10]. Group 4: Market Outlook - UBS analysts remain optimistic about the medium-term outlook for the A-share market, citing a 12% year-on-year profit growth for all A-shares in the third quarter [15][14]. - Goldman Sachs predicts a 30% increase in major stock indices by the end of 2027, indicating a potential long-term bull market for A-shares [16][14].

Group 1 - Foreign capital favors industry leaders, "Chinese state-owned enterprises," and bank stocks, with significant investments noted in companies like Kweichow Moutai, Ping An, and Wuliangye, each attracting over 80 foreign institutional investors [1][2] - As of the end of September, the top three foreign-held A-shares by market value are CATL, Kweichow Moutai, and Midea Group, with values of 265.66 billion, 88.14 billion, and 71.65 billion respectively [1][2] - The number of foreign investors holding shares in China Shipbuilding increased by over 40% from the end of June to 68 by the end of September [3] Group 2 - Bank stocks are particularly favored by foreign investors, with seven out of the top ten A-shares held by foreign capital being banks, including Nanjing Bank and Ningbo Bank, which have 2.36 billion and 1.60 billion shares held respectively [2] - A total of 42 A-shares have foreign holdings exceeding 10 billion yuan, indicating strong interest in industry leaders [2] Group 3 - UBS significantly increased its stake in RuiNeng Technology, becoming the third-largest shareholder by holding 1.1464 million shares, a 130.2% increase from the previous quarter [4][5] - Other major foreign investors in RuiNeng Technology include Goldman Sachs, JPMorgan, and Merrill Lynch, who entered the top ten shareholders for the first time [4][5] Group 4 - UBS and other foreign institutions have shown a pattern of increasing their stakes in various A-shares, indicating a trend of foreign capital "clustering" around specific stocks [4][8] - The overall market outlook remains positive, with UBS forecasting a 6% growth in A-share earnings by 2025, driven by sectors like technology and non-financial industries [9][10]

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company has achieved a revenue of 23.188 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 14.85%. The net profit attributable to shareholders is 5.751 billion yuan, up 24.50% year-on-year [5] - Continuous licensing transactions are expected to become a normalized source of income, with a significant increase in cash flow from operating activities, reaching 4.810 billion yuan in Q3 2025, a year-on-year increase of 209.78% [5] - The innovative drug pipeline is consistently delivering results, with several new drug applications being accepted, indicating stable revenue growth from innovative drugs [5] Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported a revenue of 231.88 billion yuan and a net profit of 57.51 billion yuan, with a significant increase in cash flow from operating activities [5] - The company expects revenues for 2025 to be 328.11 billion yuan, with a year-on-year growth rate of 17.2% [6] Drug Development and Licensing - The company has signed licensing agreements for innovative drugs, which are expected to contribute to future revenue growth [5] - The innovative drug pipeline includes several promising candidates, with applications for new indications being accepted [5] Profit Forecast and Valuation - The profit forecast for 2025 to 2027 shows expected revenues of 328.11 billion yuan, 366.27 billion yuan, and 416.46 billion yuan, with corresponding net profits of 89.38 billion yuan, 105.51 billion yuan, and 122.94 billion yuan [6] - The price-to-earnings ratio (PE) is projected to decrease from 46.0 in 2025 to 33.4 in 2027, indicating potential for investment [6]

Core Viewpoint - The Medical Health Index (980016) closed at 6448.2 points on November 5, with a slight decline of 0.05%, and a total trading volume of 21.263 billion yuan, indicating a low turnover rate of 0.69% [1] Group 1: Index Performance - On the same day, 18 stocks within the index rose, with Huatai Medical leading at a 5.42% increase, while 31 stocks fell, with Zai Jing Pharmaceutical leading the decline at 1.91% [1] - The top ten constituent stocks of the Medical Health Index are detailed, with WuXi AppTec holding the highest weight at 13.66% and a latest price of 94.31 yuan, showing a 0.53% increase [1] Group 2: Market Capitalization - The total market capitalization of WuXi AppTec is approximately 281.398 billion yuan, while other notable companies include Hengrui Medicine at 411.241 billion yuan and Mindray Medical at 250.090 billion yuan [1] - The index's constituent stocks are primarily in the pharmaceutical and medical sectors, indicating a focus on healthcare-related investments [1] Group 3: Capital Flow - The net outflow of main funds from the constituent stocks totaled 608 million yuan, while retail investors saw a net inflow of 692 million yuan, suggesting a shift in investment behavior [1] - Detailed capital flow data shows that stocks like Mindray Medical and Bai Jie Shen Zhou experienced significant net inflows from retail investors, despite overall net outflows from main and speculative funds [2]

来源：新浪证券 出品：新浪财经上市公司研究院 前三季度进度业绩滞后 第三季度净利润同比下滑 基本面撑不起高估值 赛力斯港股首日破发的核心症结，在于其高估值始终缺乏扎实的业绩支撑，而2025年三季报披露的经营 数据，进一步印证了这一隐患。10月31日盘后，赛力斯同步发布2025年前三季度及第三季度财务数据： 从整体来看，前三季度营业收入1105亿元，同比仅增长3.7%；归母净利润53亿元，同比增幅31.6%，看 似实现"营收微增、利润高增"的局面。但深入拆解单季度表现可见明显压力——第三季度单季营业收入 481亿元，同比增长15.8%，营收增速虽较前三季度整体水平有所提升，归母净利润却同比下滑1.7%， 单季度盈利能力出现阶段性承压，打破了市场对其"利润持续高增"的预期。更关键的是，这份业绩与市 场目标仍存在显著差距。根据卖方机构预测，赛力斯2025年全年需实现营业收入1782亿元、净利润100 亿元。但截至前三季度，其营收仅完成全年目标的60%，净利润完成率更低至53%。 在2025年新能源汽车市场竞争加剧的背景下，赛力斯第四季度的"业绩冲刺"难度远超往年。从行业环境 看，今年车企价格战持续、新车型密集投放， ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 出品：新浪财经上市公司研究院 作者：喜乐 作为2022年至今港股市场最大整车厂IPO、今年第三大港股IPO，赛力斯的港股上市之路从招股阶段的"高折价争议"，最终走向首日"破发边 缘"。11月5日，赛力斯在港交所挂牌交易，尽管最终以131.50港元/股的发行价收盘，勉强避免"破发"标签，但盘中一度探底118港元/股，较发行 价跌超10%；开盘价128.90港元/股亦低于发行价，全程依赖稳市商中金动用绿鞋资金"托底"才挽回局面。这场"惊险过关"的上市首日表现，实则 是其估值虚高、业绩承压、华为光环褪色等深层问题的集中爆发，也印证了此前招股阶段市场担忧的合理性。 港股发行价较A股折价高达22.7% 发售量调整权未全额行使暗示机构需求疲软 早在招股阶段，赛力斯的高折价水平就引发市场对其估值的质疑，而最终确定的22.7%折价（发行价131.50港元/股，较10月31日A股收盘价 155.19元/股计算），虽较最高预期略有收窄，但仍远超2025年同类大型A to H项目的常规水平——梳理今年发行规模100亿港元以上的A to H项 目，除恒瑞医药因 ...